Patient versus healthcare professional spontaneous adverse drug reaction reporting: A systematic review

Drug Safety

Volumn 35, Issue 10, 2012, Pages 807-818

  Inch, Jackie ^a   Watson, Margaret C ^a   Anakwe Umeh, Stella ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Adverse drug reactions; Health care provider; Pharmacovigilance

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

DATA EXTRACTION; DENMARK; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMBASE; HEALTH CARE PERSONNEL; HUMAN; MEDICAL LITERATURE; MEDLINE; NETHERLANDS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNITED KINGDOM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DRUG TOXICITY; HUMANS; PATIENTS; PHARMACOVIGILANCE; PHYSICIANS;

EID: 84866063854     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11631650-000000000-00000     Document Type: Review

References (22)

1. George C. Reporting adverse drug reactions: a guide for healthcare professionals. London: British Medical Association, 2006
2. Golomb BA, McGraw JJ, Evans MA, et al. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007; 30 (8): 669-75
3. World Health Organization. Consumer reporting of adverse drug reactions. WHO Drug Inf 2000; 14 (4): 211-5
4. Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011; 15 (20): 1-234, iii-iv
5. The PRISMA statement [online]. Available from URL: www.prisma-statement. org [Accessed 2012 Jul 30]
6. Ekins-Daukes S, Irvine D, Wise L. The Yellow Card Scheme: evaluation of patient reporting of suspected adverse drug reactions [abstract no. 223]. Pharmacoepidemiol Drug Saf 2006; 15: S105
7. Barrow PL, Foy M, Gandhi S, et al. The Yellow Card Scheme: experience of patient reporting of adverse drug reaction since nationwide launch [abstract no. 221]. Drug Saf 2009; 32 (10): 968
8. McLernon DJ, Bond CM, Hannaford PC, et al. Adverse drug reaction reporting in the UK: a retrospective observational comparison of Yellow Card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33 (9): 775-88
9. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009; 32 (11): 1067-74
10. de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands. Drug Saf 2008; 31 (6): 515-24
11. Health Canada. Adverse reaction and incident reporting 2010. Can Adverse Reaction Newsl 2011; 21 (3): 2-5
12. Health Canada. Canada vigilance adverse reaction online database [online]. Available from URL: http://www.hc-sc. gc.ca/dhp-mps/medeff/databasdon/ index-eng.php [Accessed 2011 Jul 29]
13. US FDA. AERS reporting by healthcare providers and consumers by year [online]. Available from URL: www. fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm070456.htm [Accessed 2011 Jul 29]
14. Danish Medicines Agency. The Danish Medicines Agency's annual pharmacovigilance report 2010 [online]. Available from URL: www. laegemiddelstyrelsen.dk/~/media/BAC4 DA2950FF4AE1BC6D559EC35AFB3B.ashx [Accessed 2012 Jul 31]
15. Danish Medicines Agency [online]. Available from URL: www.laegemiddelstyrelsen.dk [Accessed 2011 Aug 5]
16. Netherlands Pharmacovigilance Centre [online]. Available from URL: http://www.lareb.nl/kennis/signalen.asp [Accessed 2011 Aug 9]
17. US FDA. MedWatch: The FDA safety information and adverse event reporting program [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/ default.htm [Accessed 2010 Apr 20]
18. Metters J. Report of an independent review of access to the Yellow Care Scheme. London: The Stationery Office, 2004
19. van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions. Expert Opin Drug Saf 2004; 3 (4): 363-8
20. Commission of the European Communities. Proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Brussels: European Medicines Agency, 2008 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/Lex UriServ.do?uri=OJ:L:2004:136:0001:0033: en:PDF [Accessed 2012 Aug 1]
21. Moore N, Begaud B. Improving pharmacovigilance in Europe. BMJ 2010; 340: c1694
22. Pirmohamed M, Atuah KN, Dodoo ANO, et al. Pharmacovigilance in developing countries. BMJ 2007; 33 (462): 1233-4